Valam Corp. was initially founded to pursue research and development of light based antimicrobial and biofilm disruption therapies.
After revising its business strategy and plan in 2016, the company is in the process of acquiring specific technologies and products with the objective to become an exclusive commercial supplier of clinical solutions and procedures, focused on the ENT market. Valam established a strong and internationally recognized board of directors and is in the process of building a new executive team that is committed to the Company’s success.
Valam secured several exclusive supply agreements with suppliers and subcontractors. In addition, the company is in various stages of establishing multiple partnerships with major U.S. and international companies in the healthcare industry.
Valam has multiple issued, pending or licensed patents, in laser / light therapy.
The company also completed the development various tools which is dedicated for its proprietary minimally invasive robotic and non-robotic procedures for Sleep Apnea (known as RAMISH / MISH, Minimally Invasive Suspension of Hyoid).
Yosef Krespi, MD, FACS